NASDAQ: AADI
Aadi Bioscience Inc Stock Forecast, Predictions & Price Target

Analyst price target for AADI

Based on 1 analyst offering 12 month price targets for Aadi Bioscience Inc

Min Forecast
$1.75-35.19%
Avg Forecast
$1.75-35.19%
Max Forecast
$1.75-35.19%

Should I buy or sell AADI stock?

Based on 1 analyst offering ratings for Aadi Bioscience Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Hold" rating. Learn More

Be the first to know when Wall Street analysts revise their AADI stock forecasts and price targets.

AADI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-27

1 of 1

Forecast return on equity

Is AADI forecast to generate an efficient return?

Company
-30.06%
Industry
239.02%
Market
89.49%
AADI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AADI forecast to generate an efficient return on assets?

Company
-24.16%
Industry
35.08%
AADI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AADI earnings per share forecast

What is AADI's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.94
Avg 2 year Forecast
-$0.60
Avg 3 year Forecast
-$0.83

AADI revenue forecast

What is AADI's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$64.9M+158.68%
Avg 2 year Forecast
$29.9M+19.27%
Avg 3 year Forecast
$32.2M+28.44%
AADI's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AADI revenue growth forecast

How is AADI forecast to perform vs Biotechnology companies and vs the US market?

Company
0.47%
Industry
49.9%
Market
11.74%
AADI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AADI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AADI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AADI$2.70$1.75-35.19%Hold
BYSI$1.66N/AN/A
APLT$0.58$6.10+959.03%Buy
VANI$1.14$3.00+163.16%Buy
HOWL$1.52$9.50+525.00%Buy

Aadi Bioscience Stock Forecast FAQ

Is Aadi Bioscience Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: AADI) stock is to Hold AADI stock.

Out of 1 analyst, 0 (0%) are recommending AADI as a Strong Buy, 0 (0%) are recommending AADI as a Buy, 1 (100%) are recommending AADI as a Hold, 0 (0%) are recommending AADI as a Sell, and 0 (0%) are recommending AADI as a Strong Sell.

If you're new to stock investing, here's how to buy Aadi Bioscience stock.

What is AADI's earnings growth forecast for 2025-2027?

(NASDAQ: AADI) Aadi Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.55%.

Aadi Bioscience's earnings in 2025 is -$61,687,000.On average, 3 Wall Street analysts forecast AADI's earnings for 2025 to be -$23,168,548, with the lowest AADI earnings forecast at -$59,153,741, and the highest AADI earnings forecast at $7,394,218. On average, 1 Wall Street analyst forecast AADI's earnings for 2026 to be -$14,788,435, with the lowest AADI earnings forecast at -$14,788,435, and the highest AADI earnings forecast at -$14,788,435.

In 2027, AADI is forecast to generate -$20,457,335 in earnings, with the lowest earnings forecast at -$20,457,335 and the highest earnings forecast at -$20,457,335.

What is AADI's revenue growth forecast for 2025-2027?

(NASDAQ: AADI) Aadi Bioscience's forecast annual revenue growth rate of 0.47% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.74%.

Aadi Bioscience's revenue in 2025 is $25,070,000.On average, 2 Wall Street analysts forecast AADI's revenue for 2025 to be $1,598,383,371, with the lowest AADI revenue forecast at $732,027,542, and the highest AADI revenue forecast at $2,464,739,200. On average, 1 Wall Street analysts forecast AADI's revenue for 2026 to be $736,957,021, with the lowest AADI revenue forecast at $736,957,021, and the highest AADI revenue forecast at $736,957,021.

In 2027, AADI is forecast to generate $793,646,022 in revenue, with the lowest revenue forecast at $793,646,022 and the highest revenue forecast at $793,646,022.

What is AADI's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: AADI) forecast ROA is -24.16%, which is lower than the forecast US Biotechnology industry average of 35.08%.

What is AADI's Price Target?

According to 1 Wall Street analyst that have issued a 1 year AADI price target, the average AADI price target is $1.75, with the highest AADI stock price forecast at $1.75 and the lowest AADI stock price forecast at $1.75.

The Wall Street analyst predicted that Aadi Bioscience's share price could fall to $1.75 by Aug 27, 2025. The average Aadi Bioscience stock price prediction forecasts a potential downside of 35.19% from the current AADI share price of $2.70.

What is AADI's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: AADI) Aadi Bioscience's current Earnings Per Share (EPS) is -$2.28. On average, analysts forecast that AADI's EPS will be -$0.94 for 2025, with the lowest EPS forecast at -$2.40, and the highest EPS forecast at $0.30. On average, analysts forecast that AADI's EPS will be -$0.60 for 2026, with the lowest EPS forecast at -$0.60, and the highest EPS forecast at -$0.60. In 2027, AADI's EPS is forecast to hit -$0.83 (min: -$0.83, max: -$0.83).

What is AADI's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: AADI) forecast ROE is -30.06%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.